menu
    • menu

    Company profile for Septerna

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Septerna, Inc. is a biotechnology company focused on advancing novel, oral small-molecule medicines targeting the entire class of G protein-coupled receptors (GPCRs). The company’s focusing the Native Complex™ Platform on tackling previously difficult-to-drug GPCR targets, and their small molecule drug discovery efforts have rapidly advanced, resulting in a pipeline of innovative programs. Septerna is building a pipeline o...
    Septerna, Inc. is a biotechnology company focused on advancing novel, oral small-molecule medicines targeting the entire class of G protein-coupled receptors (GPCRs). The company’s focusing the Native Complex™ Platform on tackling previously difficult-to-drug GPCR targets, and their small molecule drug discovery efforts have rapidly advanced, resulting in a pipeline of innovative programs. Septerna is building a pipeline of GPCR-targeted, oral small-molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SepternaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    250 East Grand Avenue, Suite 65 South San Francisco, CA 94080
    Telephone
    Telephone
    +1 6503383533
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://septerna.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/septernainc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Septerna To Present At TD Cowen Health Care Conference
    Septerna To Present At TD Cowen Health Care Conference

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3243503/0/en/Septerna-to-Present-at-TD-Cowen-46th-Annual-Health-Care-Conference.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    Septerna Grants Inducement Under Nasdaq Listing Rule 5635(c)(4)
    Septerna Grants Inducement Under Nasdaq Listing Rule 5635(c)(4)

    10 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/10/3235766/0/en/Septerna-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    10 Feb 2026
    Share Share
    Septerna Unveils Phase 1 SEP-631 Data for Mast Cells at 2026
    Septerna Unveils Phase 1 SEP-631 Data for Mast Cells at 2026

    10 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/10/3235238/0/en/Septerna-to-Present-Data-from-Phase-1-Clinical-Trial-of-SEP-631-for-the-Treatment-of-Mast-Cell-Driven-Diseases-at-2026-AAAAI-Annual-Meeting.html

    GLOBENEWSWIRE
    10 Feb 2026
    Share Share
    Septerna Appoints Mark A. Wilson As Chief Legal Officer
    Septerna Appoints Mark A. Wilson As Chief Legal Officer

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215778/0/en/Septerna-Expands-Leadership-with-Appointment-of-Industry-Veteran-Mark-A-Wilson-as-Chief-Legal-Officer.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share
    Septerna To Present At J.P. Morgan Healthcare Conference
    Septerna To Present At J.P. Morgan Healthcare Conference

    17 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/17/3206946/0/en/Septerna-to-Present-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    17 Dec 2025
    Share Share
    Septerna To Attend Evercore Healthcare Conference
    Septerna To Attend Evercore Healthcare Conference

    25 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/25/3194257/0/en/Septerna-to-Participate-in-8th-Annual-Evercore-Healthcare-Conference.html

    GLOBENEWSWIRE
    25 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search